AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30393868 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and control groups.
Number of subjects: 40
Study 28931164 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief face-to-face patient education (3-min one-on-one verbal education by medical students and a pamphlet)
Number of subjects: 529
Study 28931164 — intervention group
Group type: COMPARATOR
Intervention: Control group (no verbal health education or pamphlet)
Number of subjects: 529
Study 28931164 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (brief face-to-face patient education)
Number of subjects: 529
Study 26073011 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine
Number of subjects: 47000
Study 24919569 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab + Rilotumumab
Number of subjects: 142
Study 24919569 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab + Ganitumab
Number of subjects: 142
Study 24919569 — intervention group
Group type: COMPARATOR
Intervention: Panitumumab + Placebo
Number of subjects: 142
Study 23236345 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly standardized motivational text message
Number of subjects: 200
Study 23236345 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 19535548 — intervention group
Group type: EXPERIMENTAL
Intervention: Short telomeres on chromosome 9p
Number of subjects: 0
Study 19535548 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile analysis of 9p telomere length
Number of subjects: 0
Study 19535548 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 18158078 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30 TID
Number of subjects: 308
Study 18158078 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30 BID + MET
Number of subjects: 308
Study 18158078 — intervention group
Group type: COMPARATOR
Intervention: OADs
Number of subjects: 308
Study 15368046 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone substitution
Number of subjects: 61
Study 11394244 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (300 mg alpha‐tocopherol daily)
Number of subjects: 18
Study 11394244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11394244 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol concentrations (high in preovulatory phase)
Number of subjects: 18
Study 11394244 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation and/or cycle-phase related changes in oestradiol concentrations
Number of subjects: 18
Study 9608882 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Melting Tablet (FMT)
Number of subjects: 18
Study 9608882 — intervention group
Group type: COMPARATOR
Intervention: Sugar Coated Tablets (SCT)
Number of subjects: 18
Study 9608882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 18
Study 8015023 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms of recombinant yeast‐derived HBV vaccine
Number of subjects: 180
Study 8015023 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms of recombinant yeast‐derived HBV vaccine
Number of subjects: 180
Study 3050522 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg twice daily)
Number of subjects: 479
Study 3050522 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (1000 units per hour by intravenous infusion)
Number of subjects: 479
Study 3050522 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus Heparin
Number of subjects: 479
Study 3050522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 479
Study 30704577 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR
Number of subjects: 872
Study 30704577 — intervention group
Group type: COMPARATOR
Intervention: FFR
Number of subjects: 872
Study 28574158 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening microneedle patch
Number of subjects: 34
Study 28574158 — intervention group
Group type: COMPARATOR
Intervention: Whitening essence
Number of subjects: 34
Study 26628861 — intervention group
Group type: EXPERIMENTAL
Intervention: Grateziano (400 mg daily)
Number of subjects: 25
Study 26628861 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratisovir (400 mg daily)
Number of subjects: 25
Study 23337088 — intervention group
Group type: EXPERIMENTAL
Intervention: Active practice receiving regular feedback on film quality
Number of subjects: 40
Study 23337088 — intervention group
Group type: COMPARATOR
Intervention: Control practice receiving no feedback
Number of subjects: 40
Study 21615854 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and estramustine
Number of subjects: 59
Study 21615854 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel-based chemotherapy
Number of subjects: 59
Study 21615854 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline quality of life
Number of subjects: 59
Study 18289446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative intravenous tramadol 2 mg kg(‐1)
Number of subjects: 60
Study 18289446 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 mL saline)
Number of subjects: 60
Study 16494982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground linseeds (20 g/d) for 2 months
Number of subjects: 40
Study 16494982 — intervention group
Group type: COMPARATOR
Intervention: Control group (dietary advice only)
Number of subjects: 40
Study 12559660 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate (600 micro g for 8 weeks)
Number of subjects: 15
Study 12559660 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for 8 weeks)
Number of subjects: 15
Study 11038077 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuMAb CD18 (2 mg/kg)
Number of subjects: 116
Study 11038077 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuMAb CD18 (1 mg/kg)
Number of subjects: 116
Study 11038077 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuMAb CD18 (0.5 mg/kg)
Number of subjects: 116
Study 11038077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 11038077 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuMAb CD18
Number of subjects: 116
Study 9075510 — intervention group
Group type: EXPERIMENTAL
Intervention: Painstop (paracetamol 12 mg, codeine 0.5 mg, promethazine 0.65 mg per 1.0 ml, dosage 1.0 ml/kg)
Number of subjects: 95
Study 9075510 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 20 mg/kg
Number of subjects: 95
Study 8369940 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy
Number of subjects: 60
Study 8369940 — intervention group
Group type: COMPARATOR
Intervention: Immediate appendicectomy
Number of subjects: 60
Study 3775139 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Teaching Programme (DTP) based on problem oriented participatory education (POPE)
Number of subjects: 0
Study 3775139 — intervention group
Group type: COMPARATOR
Intervention: Conventional classroom teaching (Control)
Number of subjects: 0
Study 29266485 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage ridge augmentation with resorbable membrane (M+)
Number of subjects: 52
Study 29266485 — intervention group
Group type: COMPARATOR
Intervention: One-stage ridge augmentation without resorbable membrane (M-)
Number of subjects: 52
Study 26465791 — intervention group
Group type: COMPARATOR
Intervention: F130
Number of subjects: 0
Study 26465791 — intervention group
Group type: COMPARATOR
Intervention: F0
Number of subjects: 0
Study 26465791 — intervention group
Group type: COMPARATOR
Intervention: F65
Number of subjects: 0
Study 23903361 — intervention group
Group type: COMPARATOR
Intervention: Aortic propagation velocity (APV) in ESRD patients
Number of subjects: 50
Study 23903361 — intervention group
Group type: COMPARATOR
Intervention: Pulse wave velocity (PWV) in ESRD patients
Number of subjects: 50
Study 23903361 — intervention group
Group type: COMPARATOR
Intervention: Carotid intima-media thickness (CIMT) in ESRD patients
Number of subjects: 50
Study 23903361 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlations between APV and CIMT
Number of subjects: 50
Study 23903361 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlations between APV and PWV
Number of subjects: 50
Study 23903361 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlations between PWV and CIMT
Number of subjects: 50
Study 22246619 — intervention group
Group type: EXPERIMENTAL
Intervention: 400‐mg EGCG as PPE
Number of subjects: 103
Study 22246619 — intervention group
Group type: EXPERIMENTAL
Intervention: 800‐mg EGCG as PPE
Number of subjects: 103
Study 22246619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 20163376 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-03491390 (5, 25 or 50 mg) orally twice daily for up to 12 weeks
Number of subjects: 204
Study 20163376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 17905607 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon after retreatment (no further treatment)
Number of subjects: 66
Study 17905607 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon after retreatment (reinstrumented to apical size 60 using K‐files)
Number of subjects: 66
Study 17905607 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon after retreatment (reinstrumented to apical size 60 using ProFile)
Number of subjects: 66
Study 17905607 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 roots served as controls)
Number of subjects: 66
Study 16224143 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial microwave ablation
Number of subjects: 14
Study 16224143 — intervention group
Group type: COMPARATOR
Intervention: Cryosurgical Maze
Number of subjects: 14
Study 12108617 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human secretin (single dose)
Number of subjects: 8
Study 12108617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10459700 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg melatonin
Number of subjects: 6
Study 10459700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 10158388 — intervention group
Group type: EXPERIMENTAL
Intervention: Site-specific thrombolysis using urokinase with Dispatch catheter
Number of subjects: 68
Study 10158388 — intervention group
Group type: EXPERIMENTAL
Intervention: Site-specific thrombolysis using urokinase with hydrogel-coated balloon
Number of subjects: 68
Study 10158388 — intervention group
Group type: COMPARATOR
Intervention: Standard techniques for treating intracoronary thrombus
Number of subjects: 68
Study 2136991 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy gallium-arsenide laser treatment
Number of subjects: 20
Study 2136991 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser treatment
Number of subjects: 20
Study 1115365 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia
Number of subjects: 28
Study 1115365 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anesthesia
Number of subjects: 28
Study 1115365 — intervention group
Group type: COMPARATOR
Intervention: Chloral hydrate premedication
Number of subjects: 28
Study 1115365 — intervention group
Group type: COMPARATOR
Intervention: Pentobarbital and meperidine
Number of subjects: 28
Study 31773372 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser application with an 810-nm GaAlAs laser device at 0, 3, 7, 14, 21, and 28 days to 8 J/cm2
Number of subjects: 30
Study 31773372 — intervention group
Group type: EXPERIMENTAL
Intervention: LED application with an 850-nm wavelength and 20 mW/cm2 output power for 10 min per day
Number of subjects: 30
Study 31773372 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy with a laser device that did not make active pulses
Number of subjects: 30
Study 29369843 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartwatch feedback application
Number of subjects: 30
Study 29369843 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 30
Study 29178842 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of pepsin and amino acid hydrochloride taken as tablets three times daily for 6 weeks
Number of subjects: 97
Study 29178842 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of pepsin and amino acid hydrochloride
Number of subjects: 97
Study 26571905 — intervention group
Group type: EXPERIMENTAL
Intervention: PBL and LEL
Number of subjects: 2010
Study 26571905 — intervention group
Group type: COMPARATOR
Intervention: LBL
Number of subjects: 2010
Study 23681296 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) at stimulus intensity ranging from 40 to 100% stimulator output in intervals of 10%.
Number of subjects: 7
Study 23681296 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar flexors at knee angle of 180° (PF180).
Number of subjects: 7
Study 23681296 — intervention group
Group type: COMPARATOR
Intervention: Plantar flexors at knee angle of 90° (PF90).
Number of subjects: 7
Study 21270385 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive underfeeding
Number of subjects: 100
Study 21270385 — intervention group
Group type: COMPARATOR
Intervention: Target feeding
Number of subjects: 100
Study 18593092 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based resources for dentists (e.g., journals, online resources like PubMed and Cochrane Collaboration)
Number of subjects: 0
Study 18593092 — intervention group
Group type: EXPERIMENTAL
Intervention: Research methodologies in evidence-based dentistry
Number of subjects: 0
Study 17201610 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (400-600 mg/day)
Number of subjects: 33
Study 17201610 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex (serum level 80-120 microg/mL)
Number of subjects: 33
Study 17201610 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both treatments
Number of subjects: 33
Study 12749423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed group (GnRH antagonist starting on day 6 of stimulation)
Number of subjects: 111
Study 12749423 — intervention group
Group type: COMPARATOR
Intervention: Flexible group (GnRH antagonist starting when a follicle of > or = 15 mm was present)
Number of subjects: 111
Study 10878693 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Centre
Number of subjects: 50
Study 10878693 — intervention group
Group type: COMPARATOR
Intervention: Hospital
Number of subjects: 50
Study 8813484 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (3 X 100 micrograms/day subcutaneously)
Number of subjects: 300
Study 8813484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 1350491 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg)
Number of subjects: 16
Study 1350491 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40 mg)
Number of subjects: 16
Study 6465819 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization
Number of subjects: 0
Study 6465819 — intervention group
Group type: COMPARATOR
Intervention: Chest physiotherapy with bronchodilatation
Number of subjects: 0
Study 6465819 — intervention group
Group type: COMPARATOR
Intervention: Chest physiotherapy without bronchodilatation
Number of subjects: 0
Study 31689808 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyung-Ok-Ko
Number of subjects: 0
Study 31689808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29910054 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servoventilation (ASV) + Optimal Medical Therapy (OMT)
Number of subjects: 126
Study 29910054 — intervention group
Group type: COMPARATOR
Intervention: Optimal Medical Therapy (OMT) alone
Number of subjects: 126
Study 29910054 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servoventilation (ASV)
Number of subjects: 126
Study 26079867 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute exercise session focused on hand training using therapeutic putty
Number of subjects: 60
Study 26079867 — intervention group
Group type: COMPARATOR
Intervention: Active upper limb exercises (Control)
Number of subjects: 60
Study 24075564 — intervention group
Group type: COMPARATOR
Intervention: Modified Blalock‐Taussig shunt
Number of subjects: 393
Study 24075564 — intervention group
Group type: COMPARATOR
Intervention: Right ventricle‐to‐pulmonary artery shunt
Number of subjects: 393
Study 24075564 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonelective timing of the stage 2 procedure
Number of subjects: 393
Study 24075564 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery (PA) stenosis
Number of subjects: 393
Study 24075564 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or greater atrioventricular valve (AVV) regurgitation
Number of subjects: 393
Study 24075564 — intervention group
Group type: EXPERIMENTAL
Intervention: AVV repair
Number of subjects: 393
Study 22356661 — intervention group
Group type: EXPERIMENTAL
Intervention: Education by a dentist
Number of subjects: 157
Study 22356661 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-teaching
Number of subjects: 157
Study 22356661 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence triangle concept (dentists, teachers, participants)
Number of subjects: 157
Study 22356661 — intervention group
Group type: COMPARATOR
Intervention: Control (approaches I and II)
Number of subjects: 157
Study 20456213 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil orodispersible tablet (ODT)
Number of subjects: 473
Study 20456213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473
Study 16221751 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor sequence learning task (30 minutes)
Number of subjects: 30
Study 16221751 — intervention group
Group type: COMPARATOR
Intervention: Nonrepetitive sequence movements (30 minutes)
Number of subjects: 30
Study 12814931 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioisotope localization (ROLL)
Number of subjects: 38
Study 10617943 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated fish oil (1.45 g eicosapentaenoic acid and 1.55 g docosahexaenoic acid/d) for 4 weeks
Number of subjects: 14
Study 10617943 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 normolipidemic subjects)
Number of subjects: 14
Study 9382759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine
Number of subjects: 26
Study 9382759 — intervention group
Group type: COMPARATOR
Intervention: Control group (age and gender-matched)
Number of subjects: 26
Study 1554923 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg/d during five months
Number of subjects: 199
Study 3754234 — intervention group
Group type: EXPERIMENTAL
Intervention: piperazinedione 9 mg/m2 iv every 3 weeks
Number of subjects: 37
Study 3754234 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin 50 mg/m2 iv every 3 weeks
Number of subjects: 37
Study 30816148 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of a combination of polyphenolic extracts from Lippia citriodora L. and Hibiscus sabdariffa L. (LC-HS)
Number of subjects: 56
Study 30816148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 29384083 — intervention group
Group type: EXPERIMENTAL
Intervention: sANSWERS method combining VF and OCT data
Number of subjects: 72
Study 29384083 — intervention group
Group type: EXPERIMENTAL
Intervention: ANSWERS method
Number of subjects: 72
Study 29384083 — intervention group
Group type: EXPERIMENTAL
Intervention: PoPLR method
Number of subjects: 72
Study 29384083 — intervention group
Group type: EXPERIMENTAL
Intervention: GPA method
Number of subjects: 72
Study 29384083 — intervention group
Group type: EXPERIMENTAL
Intervention: sANSWERS method
Number of subjects: 72
Study 29384083 — intervention group
Group type: EXPERIMENTAL
Intervention: PERM method
Number of subjects: 72
Study 29384083 — intervention group
Group type: EXPERIMENTAL
Intervention: MaHMIC and MaGIC analyses
Number of subjects: 72
Study 27867308 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 36
Study 27867308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 25238909 — intervention group
Group type: COMPARATOR
Intervention: Leucovorin 0 mg/m2
Number of subjects: 80
Study 25238909 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucovorin 60 mg/m2
Number of subjects: 80
Study 25238909 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucovorin 200 mg/m2
Number of subjects: 80
Study 25238909 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucovorin 500 mg/m2
Number of subjects: 80
Study 22729297 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (6 mg/ml)
Number of subjects: 185
Study 22729297 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 1 ml)
Number of subjects: 185
Study 20164321 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin
Number of subjects: 5
Study 20164321 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain cornstarch
Number of subjects: 5
Study 20164321 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amylose cornstarch
Number of subjects: 5
Study 20164321 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular cornstarch
Number of subjects: 5
Study 20164321 — intervention group
Group type: EXPERIMENTAL
Intervention: All starch treatments
Number of subjects: 5
Study 20164321 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 5
Study 17673380 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 378
Study 17673380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study 17673380 — intervention group
Group type: COMPARATOR
Intervention: Placebo crossover to Infliximab
Number of subjects: 378
Study 16574937 — intervention group
Group type: EXPERIMENTAL
Intervention: 1018 ISS (36 mg by nebulization weekly for 4 weeks)
Number of subjects: 40
Study 16574937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14606080 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule oxymatrine
Number of subjects: 216
Study 14606080 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of oxymatrine
Number of subjects: 216
Study 14606080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 11023565 — intervention group
Group type: EXPERIMENTAL
Intervention: 7F double‐pigtail stent placement for 6 months
Number of subjects: 20